Whetting pharma's appetite

Early Bird Dealmaking

Whetting pharma's appetite

Though deals for late stage products promise a more timely impact on earnings, the need for innovation remains urgent for pharma licensing specialists, who say they are willing to pay more for earlier technology because the quality of biotech R&D is increasing.

Indeed, Merck & Co. Inc., AstraZeneca plc

Read the full 528 word article

User Sign In

Article Purchase

This article may not be distributed to non-subscribers

PURCHASE THIS ARTICLE FOR LIMITED ONE-TIME DISTRIBUTION AND WEBSITE POSTING $995.00 USD

PURCHASE